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Abstract  21 
Objectives Active management of the third stage of labour is recommended for preventing postpartum 22 
haemorrhage (PPH). However, the specific effects of each of its components have not been adequately 23 
evaluated. The TRACOR Study aimed to assess the impact of controlled cord traction on the incidence 24 
of PPH and other characteristics of the third stage of labour, in a high-resource setting. 25 
Design Randomized controlled trial conducted between January 1, 2010, and January 31, 2011.  26 
Setting Five French university hospital maternity units  27 
Participants Women aged ≥18, with a planned vaginal delivery, at a gestational age ≥ 35 weeks, with 28 
a singleton fetus.  29 
Interventions Women were randomly assigned to have third stage of labor managed either by 30 
controlled cord traction (CCT), or by standard placenta expulsion (SPE) i.e. awaiting the spontaneous 31 
placental separation before facilitating its expulsion. Prophylactic oxytocin just after birth of the baby 32 
was administered in the 2 arms.  33 
Main outcome measures The primary outcome was the incidence of PPH ≥ 500 mL as measured in a 34 
collector bag.  35 
Results The incidence of PPH was not different in the CCT group (9.8% (196/2005) and in the SPE 36 
group (10.3% (206/2008), RR 0.95, 95% CI (0.79 to 1.15). The need for manual removal of placenta 37 
was significantly less frequent in the CCT than in the SPE group (4.2%(85/2033) and 6.1%(123/2024), 38 
RR 0.69, 95%CI (0.53 to 0.90)); as was third stage > 15 minutes (4.5% (91/2030) and 14.3% 39 
(289/2020), RR 0.31, 95%CI 0.25 to 0.39)). Women in the CCT group reported a significantly lower 40 
intensity of pain and discomfort during the third stage than those in the SPE group. No uterine 41 
inversion occurred in either arm. 42 
Conclusions In a high-resource setting, the use of CCT for the management of placenta expulsion had 43 
no significant effect on the incidence of PPH and other markers of postpartum blood loss. Therefore, 44 
there is no evidence to recommend routine CCT for the management of placenta expulsion in order to 45 
prevent PPH.  46 
Trial registration ClinicalTrials.gov NCT01044082. 47 
48 
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“What this paper adds “ box 49 
What is already known on this subject 50 
 Active management of the third stage of labour includes the administration of an uterotonic 51 
drug immediately after child birth and controlled cord traction (CCT), and is recommended for 52 
the prevention of PPH.  53 
 The management of third stage of labour without CCT does not increase the risk of severe 54 
PPH in low and middle income countries, and therefore could be omitted in non-hospital 55 
settings. 56 
 However, the impact of CCT on PPH incidence and other characteristics of third stage in the 57 
context of high-resource settings is unknown. 58 
What this study adds 59 
 In a high-resource setting, the use of CCT for the management of placenta expulsion has no 60 
significant effect on the incidence of PPH and other markers of postpartum blood loss. 61 
Therefore, there is no evidence to recommend routine CCT for the management of placenta 62 
expulsion in order to prevent PPH. 63 
 However, CCT is safe, reduces the length of third stage, the need for manual removal of 64 
placenta and for additional uterotonics after placenta delivery, and results in a better 65 
experience of the third stage for women.  66 
67 
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INTRODUCTION 68 
Postpartum haemorrhage (PPH) remains a major complication of childbirth worldwide. (1) 69 
Population-based studies in high-resource countries report a prevalence of severe PPH from 0.5% to 70 
1% of deliveries,(2-5) making it the main component of severe maternal morbidity. Uterine atony is 71 
the leading cause of PPH, accounting for 60 to 80% of cases(6). Prevention of atonic PPH is thus 72 
crucial, and preventive measures are recommended for all women giving birth, given that individual 73 
risk factors are poor predictors. 74 
Active management of the third stage of labour (AMTSL) has been proposed for the prevention of 75 
PPH(7). Its standard definition combines the following three procedures: administration of an oxytocic 76 
drug immediately after child birth, early cord clamping and cutting, and controlled cord traction. 77 
Several trials(8-11) combined in a meta-analysis(12) showed that AMTSL is associated with a 60% 78 
reduction in the incidence of PPH compared with expectant management. Given its efficacy, AMTSL 79 
has been included in international(13, 14) and national(15-17) guidelines for the prevention of PPH. 80 
However, an adequate evaluation of the specific efficacy of each of its components has not been done. 81 
The independent efficacy of preventive oxytocics has been shown with a good level of evidence(18) 82 
and it is therefore often considered the essential component of AMTSL. This is not the case for 83 
controlled cord traction (CCT).(19) Although most guidelines for prevention of PPH include CCT, its 84 
actual implementation is highly variable,  varying in Europe from 12% in Hungary to 95% in 85 
Ireland.(20) In countries, such as France, where CCT  is not recommended, pulling the cord in the 86 
absence of any sign of placenta separation is considered poor practice because of the potential risk of 87 
uterine inversion.(21) 88 
The variation in use of CCT may be explained by the paucity of available evidence for assessing either 89 
the efficacy of CCT for the prevention of PPH or its potential risks. Until recently, only two trials 90 
conducted in the 1960’s (19, 22) and with important limitations had assessed the specific effect of 91 
CCT and they had conflicting results. Very recently, a large randomized controlled trial conducted in 92 
eight low and middle income countries reported that the omission of CCT as part of AMTSL did not 93 
increase the risk of severe PPH(23). The authors concluded that CCT could be omitted in non-hospital 94 
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settings. However, the results of this trial may be relevant for low/middle income countries and not 95 
applicable to other countries.  96 
The TRACOR Study aimed to assess the impact of controlled cord traction on the incidence of PPH 97 
and other characteristics of the third stage of labour, in a high-resource setting. 98 
 99 
METHODS 100 
Trial design 101 
The TRACOR (TRAction of the CORd) trial was a multicenter randomized controlled trial with two 102 
parallel groups and took place in five French university hospitals between January 1, 2010, and 103 
January 31, 2011.  104 
CCT was not a standard part of third-stage management in any of the participating units before the 105 
trial. Before the beginning of the trial, all staff likely to recruit women into the trial (midwives and 106 
obstetricians) were trained in the trial procedures and more particularly in the technique of CCT. In 107 
each participating centre, several training meetings were led by a team from the steering committee 108 
pairing a midwife with an obstetrician. Films demonstrated the placement of the collector bag and the 109 
practice of CCT. Following this initial training, a period of one month was devoted to using CCT in 110 
actual practice. Before the inclusion period, a meeting was organized in each unit to verify the 111 
attendants’ adherence to the protocol and their ease in practicing the relevant procedures.  112 
Participants 113 
Women aged 18 or more, with a planned vaginal delivery, at a gestational age ≥ 35 weeks, with a 114 
singleton foetus, were eligible for inclusion. We excluded women with a severe haemostasis disease, 115 
those with placenta praevia, in utero foetal death, and multiple gestations. We also excluded women 116 
who did not understand French. Eligible women were approached and offered information about the 117 
study during a prenatal visit in the third trimester of pregnancy by a midwife or an obstetrician. This 118 
information was repeated after their arrival in delivery room for the planned vaginal delivery; the 119 
women then confirmed their participation and provided informed written consent.  120 
Interventions 121 
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We compared CCT with standard management of placental expulsion. 122 
In the intervention arm, CCT was implemented immediately after the delivery of the baby upon 123 
obtaining a uterine contraction, as initially described,(19) according to the following instructions: 1) 124 
after birth, CCT is started with a firm uterine contraction without waiting for placenta separation; 2) 125 
with one hand, grasp the lower segment between the thumb and index finger and exert steady pressure 126 
upwards; 3)at the same time, hold the cord in the other hand, and exert steady cord traction 127 
downwards and backwards, exactly countered by the upwards pressure of first hand, so that the 128 
position of the uterus remains unchanged. 4) If the placenta is not expelled on the first attempt, repeat 129 
CCT with counter-pressure with the next uterine contraction. 130 
In the control arm, the attendant awaited the signs of spontaneous placental separation and descent into 131 
the lower uterine segment. Once the placenta was separated, it was then delivered through the 132 
mother’s efforts (helped by fundal pressure or soft tension on the cord to facilitate placental expulsion 133 
through the vagina if needed). This standard placental expulsion (SPE) is the usual management in 134 
France, as taught in university hospitals and midwifery schools, and it was the routine procedure in the 135 
five participating centers before the trial. 136 
All other aspects of third stage management were identical in both arms: IV injection of 5 IU oxytocin  137 
within 2 minutes after birth; clamping and cutting the cord within the 2 minutes following birth; 138 
placement of a graduated collection bag (manufactured by MVF Merivaara France, 100 mL 139 
graduation) just after birth, left in place until the birth attendant judged that the postpartum bleeding 140 
had stopped and that there was no reason to further monitor it(24), and always at least for 15 minutes; 141 
manual removal of the placenta at 30 minutes after birth if not expelled. A blood sample was taken 142 
from all women on the second day after delivery for the measurement of haemoglobin (Hb) and 143 
haematocrit (Ht).  144 
Outcomes 145 
The primary outcome of the trial was the incidence of PPH defined by blood loss ≥ 500 ml, measured 146 
with a graduated collector bag (25). The main secondary outcomes were other objective measures of 147 
postpartum bleeding: measured blood loss ≥ 1000 mL at bag removal; mean measured blood loss at 15 148 
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minutes after birth (the bag had to be left in place at least 15 minutes to have one measure of blood 149 
loss at the same time point in all women); mean measured postpartum blood loss at bag removal; mean 150 
changes in peripartum haemoglobin and haematocrit (difference between Hb/Ht before delivery and 151 
D2).  Other secondary outcomes included: supplementary uterotonic treatment, postpartum transfusion 152 
(until discharge),  arterial embolization or emergency surgery for PPH; other characteristics of the 153 
third stage, including its duration, manual removal of the placenta; and women’s experience of the 154 
third stage, assessed by a self-administered questionnaire on D2 postpartum. Safety outcomes included 155 
uterine inversion, cord rupture, and pain. 156 
The detail of procedures used to manage the third stage, as well as all clinical outcomes identified 157 
during the immediate postpartum, were prospectively collected by the midwife or the obstetrician in 158 
charge of the delivery and recorded in the woman’s electronic form in the labour room. Other data 159 
were collected by a research assistant, independent of the local medical team. An independent Data 160 
Monitoring Committee, which met monthly, was responsible for reviewing adherence to the trial 161 
procedures, the recruitment and safety data; the quality of collected outcome data was checked in each 162 
centre for 10% of the included women, randomly selected, and in all PPH cases.  163 
Sample size 164 
We assumed a 7% incidence of PPH in the absence of CCT. This incidence is that found in the cohort 165 
as a whole in the Pithagore6 trial in 6 French perinatal networks in 2006 from a total of approximately 166 
147 000 births.(26) We hypothesized that CCT might explain half of the 60% reduction in PPH 167 
incidence described in the meta-analysis measuring the overall effect of active management. To show 168 
a reduction of at least 30% in the incidence of PPH in the CCT arm -that is, a PPH incidence of 4.9% 169 
or less in this arm , with  =0.05, 1-=0.80, and a bilateral test, the study required 1990 women with 170 
vaginal deliveries in each group, for a total of 3980 patients.  171 
Given the expected proportion of women with a caesarean delivery in labour after randomization 172 
(estimated at 5% to 10%), a higher number of women needed to be randomized to include the needed 173 
number of women with vaginal deliveries. The decision to stop inclusions was made by the 174 
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independent Data Monitoring Committee, which was able to access the electronic inclusion system to 175 
determine the real-time cumulative number of randomized women and their mode of delivery.  176 
This sample size provided a 70% statistical power to detect a reduction in the incidence of severe PPH 177 
(defined by blood loss ≥ 1000 ml) from 2% to 1% or less of deliveries. 178 
Randomization 179 
Randomization took place after women completed the participation form, during labour and before 180 
delivery. It was performed centrally through an automated web-based system, which ensured 181 
allocation concealment. Allocation was stratified by centre. 182 
Statistical methods  183 
The two groups were compared for main and secondary outcomes in an intention-to-treat analysis. The 184 
effects of CCT were expressed as mean differences with their 95% confidence intervals for 185 
quantitative outcomes, and as relative risks with their 95% confidence intervals for categorical 186 
outcomes. To test the consistency of the primary outcome across centres, we used the Mantel-187 
Haenszel homogeneity test. The incidence of each adverse event (cord rupture and uterine inversion) 188 
was expressed as a proportion with binomial exact confidence intervals.  189 
An analysis including women who had a caesarean delivery after randomization (for a total of 2172 190 
and 2180 women in the CCT and SPE groups, respectively), for secondary outcomes available in these 191 
women (mean change in Hb, mean change in Ht, postpartum transfusion, arterial embolization or 192 
emergency surgery) was conducted.  193 
A post-hoc “per protocol” analysis was conducted among women who were managed in accordance 194 
with the protocol and the allocation, i.e who had all the following procedures: prophylactic oxytocin 195 
administration at birth, cord clamping and cutting within 2 minutes, management of placenta 196 
expulsion in accordance with the allocation group (CCT or SPE) and blood collection bag left in place 197 
at least 15 minutes.  198 
Software used for analysis was Stata 10.1 (Stata Corporation, USA). 199 
Ethics  200 
9 
 
The trial protocol was approved by the Paris-Ile de France III Committee for the Protection of 201 
Research Subjects (Ethics Committee) in September 2009 (n°B90885-20). 202 
Registration 203 
This trial is registered (ClinicalTrials.gov), number NCT01044082. 204 
The full trial protocol can be accessed at: http://www.u953.idf.inserm.fr/page.asp?page=5211  205 
 206 
RESULTS 207 
Figure 1 shows the trial profile. The trial was carried out in all five hospitals between 1 January 2010 208 
and 31 January 2011. In all, 4355 women in labour were enrolled and randomly assigned. After 209 
randomization and before delivery, 294 (6.8%) women became ineligible because an intrapartum 210 
caesarean was performed, and 3 others declined to participate. Thus 4058 randomized participants 211 
delivered vaginally: 2034 assigned to CCT and 2024 to SPE. Baseline demographic and obstetric 212 
characteristics were similar in the two groups (Table1).  213 
The management of the third stage of labour is described in Table 2. Overall, the adherence to the 214 
protocol was high in both groups. The reasons for deviating from the allocated intervention are 215 
detailed in Figure1. 216 
Primary outcome data were collected for 4013 (98.9%) participants. The proportion of women with a 217 
measured postpartum blood loss of 500mL or more at bag removal did not differ between the 2 groups 218 
(196/2005, 9.8% in the CCT group and 206/2008, 10.3% in the SPE group, relative risk 0.95, 95% CI 219 
(0.79;1.15))(Table 3). There was no significant heterogeneity between centres for this result (Table3). 220 
Similarly, the incidence of PPH ≥ 1000mL at bag removal did not differ between the 2 groups; nor did 221 
the mean measured blood loss at 15 minutes and at removal of the bag (Table3). 222 
Outcome data related to blood count indicators before and after delivery were available for 223 
1963/2034(96.5%) women in the CCT group and 1953/2024 (96.5%) in the SPE group (at least one 224 
peripartum change in Hb or Ht available). Twenty women (11 in the CCT group and 9 in the SPE 225 
group) had transfusion before day 2 and were excluded from this analysis. There was no significant 226 
difference in the mean peripartum change in Hb or Ht (Table3). The proportion of women with a 227 
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peripartum drop in Hb of 4g/dl or more did not differ between the 2 groups, 2.1% (41/1961) in the 228 
CCT group and 1.8% (35/1953) in the SPE group, (RR 1.17, 95%CI (0.75;1.82)). 229 
 Women in the CCT group had fewer manual removals of the placenta than those in the SPE group 230 
(RR 0.69, 95%CI (0.53; 0.90)) (Table 3). Third stage was shorter in the CCT group. 231 
Regarding safety, no uterine inversion occurred among the 1943 women who had controlled cord 232 
traction (incidence 0.0%, one sided 97.5%CI (0.0%-0.18%)). Cord rupture occurred in 89 (incidence 233 
4.6%, 95% CI (3.6%; 5.5%); among those 89 women, manual removal of the placenta was needed in 234 
43 (48%). No other adverse events occurred in the two groups. 235 
Women in the CCT group reported a significantly lower intensity of pain and discomfort during the 236 
third stage than those in the SPE group; they were less likely to have felt tired and anxious and to 237 
report that the duration of third stage was long (Table 4). 238 
The per-protocol analysis was conducted in 1437/1999(71.9%) women in the CCT arm, and 239 
1574/1990 (79.1%) in the SPE arm. The proportion of women with a measured postpartum blood loss 240 
of 500mL or more at bag removal did not differ between the two groups (11.7% (168/1431) in the 241 
CCT group and 10.7% (168/1570) in the SPE group, relative risk 1.10, 95% CI (0.90 ;1.34 )).  242 
Finally, the analysis including women who had a caesarean delivery after randomization provided 243 
results similar to those of the main analysis (data not shown). 244 
 245 
DISCUSSION  246 
In this large multicenter randomized trial, we found that the use of controlled cord traction as one 247 
component of the active management of third stage of labour had no significant effect on the incidence 248 
of PPH. However, CCT reduced the duration of the third stage and the need for manual removal of 249 
placenta. Moreover, women in the CCT group reported a significantly lower intensity of pain and 250 
discomfort as well as less fatigue and anxiety. 251 
This trial included a large population of pregnant women with few exclusion criteria. Hence, the 252 
results are likely to be generalizable to women with vaginal deliveries in similar contexts of care. 253 
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Moreover, the adherence to the allocated intervention and other standardized aspects of third stage 254 
management was high, making it possible to isolate the effect of CCT.   255 
It was not possible to blind this intervention as the procedures being tested require different actions by 256 
the attendants. However, the trial primary and main secondary outcomes (change in peripartum Hb 257 
and Ht ) were objective measures of postpartum blood loss as opposed to other definitions of PPH 258 
based on visual estimation or interventions, influenced by caregiver decisions.  Although the quality of 259 
the CCT technique was not formally evaluated, a real difference in the management of placenta 260 
expulsion between the 2 groups is very likely given the emphasis on the initial training. Moreover, the 261 
attendants in the two groups clearly reported different procedures, and the length of the third stage was 262 
significantly shorter and the incidence of cord rupture higher in the CCT group.   263 
Two small trials in the 1960’s (19, 22, 27) assessed the specific effects of CCT during the third stage.  264 
Both had important methodological weaknesses including inadequate method of randomization, visual 265 
estimation of blood loss for determining outcome measures and limited sample sizes. Very recently, a 266 
large randomized controlled trial conducted in eight low and middle income countries compared CCT 267 
with “hands-off “ management of third stage(23) . The results showed that the omission of CCT did 268 
not result in an increased risk of measured blood loss of 1000 mL or more. However, heterogeneity 269 
between centres in other components of third stage management (type of uterotonic used, combination 270 
with uterine massage), absence of report on the actual duration of blood loss measurement in each arm 271 
and absence of outcomes based on blood counts, may limit the interpretation of the results. In addition, 272 
although it is of major importance to conduct research studies in low and middle income countries, the 273 
generalizability of their results for high income settings needs to be tested. Indeed, characteristics of 274 
women, management of labour, resources and organization of care in the labour ward clearly differ 275 
between low and high resource countries, and these differences may impact the risk and the 276 
characteristics of PPH. Mechanisms of PPH and effective preventive procedures may differ between 277 
settings. It is noteworthy that the incidence of PPH ≥ 500 mL in the reference group of the previous 278 
CCT trial was about 30% higher than the incidence found in the Tracor trial, which might indicate 279 
higher exposure to the risk of PPH.  For these reasons, our results provide valuable additional evidence 280 
12 
 
that CCT is not an essential component of management of the third stage of labour for prevention of 281 
PPH, in high resource countries.  282 
Cord rupture occurred in about 1 in 22 women who had CCT. This rate may appear notable at first. 283 
However, in the majority of cases (52%), delivery of the placenta occurred without any extra 284 
intervention; and overall, the rate of manual removal of placenta was lower in women who had CCT. 285 
In consequence, cord rupture should not be considered an important adverse effect of CCT and does 286 
not imply manual removal of placenta. 287 
The 30% reduction in the need for manual removal of placenta found in the CCT arm may provide a 288 
meaningful decrease in morbidity considering the need for analgesia and antibiotics, separation of 289 
mother and baby, and the risk of infection associated with this intervention (28). However, we cannot 290 
exclude the possibility that such a difference may have been less important (or even not significant) if 291 
the French policy was more conservative, allowing a duration of third stage greater than 30 minutes 292 
before manually removing the placenta, in particular in the SPE group. Our finding of a lower risk of 293 
manual removal of placenta when its expulsion is managed with CCT is in contrast with the 294 
conclusions of the trial cited above(29). However, in this study, manual removal of placenta was 295 
performed in less than 1% of deliveries in both arms, which is low in comparison with previous 296 
reports from high resource countries (30, 31), and may actually illustrate the variations in policies for 297 
the management of the third stage of labour between settings (32). Our trial also showed that CCT 298 
significantly reduced the duration of third stage. This result may have implications for optimizing the 299 
organization of postpartum surveillance and care, in particular in hospitals where the number of 300 
midwives or birth attendants in labour wards is limited. In addition, the shorter third stage and lesser 301 
need for manual removal of placenta associated with CCT are likely to be the main reasons why 302 
women reported a better experience of the third stage of labour in the CCT arm, although we cannot 303 
exclude a patient preference bias since the study was not blinded. 304 
Another controversial aspect of the management of the third stage of labour is the timing of cord 305 
clamping. Recent results from a trial conducted in Sweden showed that, even in a region with low 306 
prevalence of iron deficiency,  delayed cord clamping reduced the prevalence of neonatal anaemia and  307 
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improved iron status at 4 months of age in term deliveries (33), confirming the findings of previous 308 
trials conducted in low and middle income populations(34). CCT, as it is classically performed, is not 309 
compatible with delayed cord clamping. Our finding that CCT has no significant effect on maternal 310 
postpartum haemorrhage constitutes reassuring information for clinicians willing to implement a 311 
policy of delayed cord clamping, from both maternal and neonatal perspectives.  312 
In a high-resource setting, the use of CCT for the management of placenta expulsion has no significant 313 
effect on the incidence of PPH and other markers of postpartum blood loss. Therefore, there is no 314 
evidence to recommend routine CCT for the management of placenta expulsion in order to prevent 315 
PPH.  316 
317 
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Figure 1: Trial flow diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* During the inclusion period, 12 391 women meeting the inclusion criteria had vaginal deliveries at the 
5 participating hospitals; the trial thus recruited 32.7% (4058/12391) of the eligible women. The exact 
number of women assessed for eligibility was not collected. 
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Table 1. Baseline characteristics of women 
 
Characteristics 
Controlled Cord Traction 
(N= 2034) 
Standard Placenta Expulsion 
(N= 2024) 
Hospital   
A 485/2034 (23.8) 489/2024 (24.1) 
B 213/2034 (10.5) 202/2024 (10.0) 
C 345/2034 (17.0) 332/2024 (16.4) 
D 446/2034 (21.9) 443/2024 (21.9) 
E 545/2034 (26.8) 558/2024 (27.6) 
Age (years) ( mean (SD) (n)) 30.2 (5.2) (2034) 30.0 (5.2) (2024) 
French nationality 1838/2000 (91.9) 1814/1995 (90.9) 
Body Mass Index (mean (SD)(n)) 22.8 (4.3) (2031) 22.7 (4.1) (2017) 
Nulliparous 1074/2030 (52.9) 1031/2010 (51.3) 
Previous PPH
a 
43/2030 (2.1) 39/2010 (1.9) 
Uterine scar 132/2033 (6.5) 120/2021 (5.9) 
Prenatal Hb
b
 (g/dL) (mean (SD) (n)) 12.0 (1.0) (2005) 12.0 (1.0) (1990) 
Prenatal Ht
c
 (%) (mean (SD) (n)) 35.6 (1.0) (1952) 35.5 (2.9) (1933) 
GA
d
 at delivery (wks) (mean (SD) (n)) 39.4 (1.2) (2034) 39.4 (1.2) (2024) 
Induction of labour 381/2034 (18.7) 406/2024 (20.1) 
Epidural analgesia 1975/2033 (97.1) 1957/2023 (96.7) 
Oxytocin during labour (1
st
 and 2
nd
 stages) 1352/2033 (66.5) 1362/2020 (67.4) 
Instrumental delivery 367/2034 (18.0) 381/2024 (18.8) 
Episiotomy 597/2034 (29.3) 586/2024 (29.0) 
Perineal tear 1036/2033 (51.0) 1024/2024 (50.6) 
Birth weight (grams) (mean (SD) (n)) 3365 (428) (2032) 3390 (433) (2022) 
Birth weight ≥ 4000 grams 159/2032 (7.8) 157/2022 (7.8) 
Data are n/N (%) unless otherwise stated 
a 
Postpartum haemorrhage 
b
 Haemoglobin 
c  
Haematocrit 
d 
Gestational age 
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Table 2. Adherence to allocated intervention and other aspects of third stage management 
 
 Controlled Cord Traction Standard Placenta Expulsion 
Prophylactic oxytocin administration at birth 1977/2029 (97.4) 1961/2022 (97.0) 
Cord clamping and cutting within 2 minutes of birth 1933/2026 (95.4) 1944/2019 (96.3) 
Cord management according to protocol 1943/2031 (95.7)
 a
 1991/2024 (98.4)
 a
 
Blood collection bag 2016/2028 (99.4) 2015 (2020 (99.7) 
Duration of blood collection (min) (mean (SD) (n)) 27 (16) (1990) 29 (16) (1987) 
Blood collection bag in place ≥ 15 minutes 1609/2002 (80.4) 1717/1992 (86.2) 
Data are n/N (%) unless otherwise stated 
a
 The reasons why 88 women in the CCT group and 33 women in the SPE group did not receive the allocated intervention are mentioned in Figure 1 
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Table 3. Trial outcomes 
 Controlled Cord Traction Standard Placenta Expulsion Risk ratio (95% CI) Mean difference (95% CI) 
Blood loss ≥ 500mL 196/2005 (9.8) 206/2008 (10.3) 0.95 (0.79-1.15) / 
By hospital   0.31
a 
 
A 46/473 (9.7) 37/482 (7.7) 1.27 (0.84-1.92) / 
B 20/199 (10.1) 14/196 (7.1) 1.41 (0.73-2.71) / 
C 40/344 (11.6) 49/330 (14.9) 0.78 (0.53-1.16) / 
D 38/445 (8.5) 42/443 (9.5) 0.90 (0.59-1.37) / 
E 52/544 (9.6) 64/557 (11.5) 0.83 (0.59-1.18) / 
Blood loss ≥ 1000 mL 34/2005 (1.7) 37/2008 (1.8) 0.92 (0.58-1.46) / 
Blood loss at 15 minutes (mL)  (mean (SD) (n)) 163 (4) (2005) 161 (4) (2001) 
/ 
1.7 (-8.8;12.2) 
Total blood loss (mL) (mean (SD) (n)) 207 (5) (2005) 217 (6) (2008) 
/ 
-9.4 (-24.8;6.0) 
Blood transfusion for PPH 12/2034 (0.6) 9/2024 (0.4) 1.33 (0.56-3.14) / 
Arterial embolization/surgery for PPH 3/2034 (0.1) 5/2024 (0.3) 0.60 (0.14-2.49) / 
Peripartum change in Hb
b
(g/dL) (mean (SD) (n)) 0.9 (0.0) (1961) 0.9 (0.0) (1953) 
/ 
-0.02 (-0.10;0.07) 
Peripartum change in Ht
c 
(%) (mean (SD) (n)) 2.1 (0.1) (1904) 2.2 (0.1) (1890) 
/ 
-0.05 (-0.29;0.19) 
Duration of third stage (min) (mean (SD) (n)) 5.5 (0.1) (2030) 8.7 (0.1) (2020) 
/ 
-3.26 (-3.62; -2.90) 
Third stage ≥ 15 min 91/2030 (4.5) 289/2020 (14.3) 0.31 (0.25-0.39) / 
Manual removal of placenta 85/2033 (4.2) 123/2024 (6.1) 0.69 (0.53-0.90) / 
Additional uterotonics after placenta delivery 727/2030 (35.8) 805/2024 (39.8) 0.92 (0.83-0.97) / 
Maternal pain during 3
rd 
stage 109/1892 (5.8) 138/1868 (7.4) 0.78 (0.61-0.99) / 
Cord rupture 89/2034 (4.4) 2/2024 (0.1) 44.3 (10.9-179.6) / 
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Uterine inversion 0/2034 (0.0) 0/2024 (0.0) / / 
Data are n/N (%) unless otherwise stated 
a 
p for Mantel-Haenszel test of homogeneity across centers 
b 
Prepartum Hb measured within 8
th
 month of gestation and arrival in labour ward in 1778 (90.7%) and 1760 (90.1%), at arrival in labour ward in 95 (4.8%) and 99 (5.1%) and 
between the 5
th
-7
th
 months of gestation in 88 (4.5%) and 94 (4.8%), in the CCT and SPE groups, respectively  ; postpartum Hb measured at Day 2 in 1793 (91.4%) and 1787 
(91.5%), and on another day between 1 and 8 days in 168 (8.6%) and 166 (8.5%) , in the CCT and SPE groups, respectively.    
c
 Prepartum Ht measured within 8
th
 month of gestation and arrival in labour ward in 1724 (90.5%) and 1707 (90.3%), at arrival in labour ward in 95 (5.0%) and 99 (5.2%) and 
between the 5
th
-7
th
 months of gestation in 85 (4.5%) and 84 (4.4%), in the CCT and SPE groups, respectively; postpartum Ht measured at Day 2 in 1737 (91.2%) and 1725 (91.3%), 
and on another day between 1 and 8 days in 167 (8.8%) and 165 (8.7%) , in the CCT and SPE groups, respectively.     
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Table 4. Women’s experience of third stage 
 
  Controlled Cord Traction Standard Placenta Expulsion P
a 
Completed 
forms 
 
1838/2034 (90.4) 1844/2024 (91.2) 0.41 
Felt tired Not at all 466/1829 (25.5) 426/1838 (23.2)  
 A little 656/1829 (35.9) 621/1838 (33.8)  
 Moderately 378/1829 (20.6) 445/1838 (24.2) 0.017 
 Very 252/1829 (13.8) 285/1838 (15.5)  
 Extremely 77/1829 (4.2) 61/1838 (3.3)  
Felt anxious Not at all 1191/1821 (65.4) 1073/1821 (58.9)  
 A little 398/1821 (21.9) 475/1821 (26.1)  
 Moderately 154/1821 (8.5) 168/1821 (9.2) <0.001 
 Very 59/1821 (3.2) 94/1821 (5.2)  
 Extremely 19/1821 (1.0) 11/1821 (0.6)  
Felt 3
rd
 stage 
was long 
Not at all 1590/1830 (86.9) 1451/1833 (79.2) 
 
 A little 137/1830 (7.5) 219/1833 (11.9)  
 Moderately 68/1830 (3.7) 110/1833 (6.0) <0.001 
 Very 23/1830 (1.2) 43/1833 (2.4)  
 Extremely 12/1830 (0.7) 10/1833 (0.5)  
Felt satisfied Not at all 4/1832 (0.2) 3/1840 (0.2)  
 A little 6/1832 (0.3) 11/1840 (0.6)  
 Moderately 63/1832 (3.4) 81/1840 (4.4) 0.21 
 Very 716/1832 (39.1) 751/1840 (40.8)  
 Extremely 1043/1832 (57.0) 994/1840 (54.0)  
Discomfort
b ≤ 2 1408/1830 (76.9) 1285/1834 (70.1)  
 3-7 371/1830 (20.3) 475/1834 (25.9) <0.001 
 ≥ 8 51/1830 (2.8) 74/1834 (4.0)  
Pain intensity
c ≤ 2 1475/1828 (80.7) 1362/1837 (74.1)  
 3-7 309/1828 (16.9) 413/1837 (22.5) <0.001 
 ≥ 8 44/1828 (2.4) 62/1837 (3.4)  
Data are n/N (%) 
a 
Chi2 test 
b
 graded from 0 (no discomfort) to 10 
c 
graded from 0 (no pain) to 10 
 
